New drug BL-B01D1 targets Hard-to-Treat solid tumors in early trial
NCT ID NCT05785039
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II trial is testing a drug called BL-B01D1 in 76 adults with advanced urinary system or other solid tumors that have not responded to standard treatments. The study aims to find the best dose and see how well the drug shrinks tumors, while also monitoring safety and side effects. Participants receive the drug by IV infusion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (a drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced urinary system or other solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early Phase II trial with only 76 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for URINARY SYSTEM TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University ShangHai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••